Welcome To b2b168.com, Join Free | Sign In
中文(简体) |
中文(繁體) |
Francés |Español |Deutsch |Pусский |
| No.9187241
- Product Categories
- Friendly Links
- home > Supply > Supply of the 2013 edition of the Chinese the polypeptide drug market investment profitability analysis and development potential research report
Supply of the 2013 edition of the Chinese the polypeptide drug market investment profitability analysis and development potential research report
Information Name: | Supply of the 2013 edition of the Chinese the polypeptide drug market investment profitability analysis and development potential research report |
Published: | 2012-10-25 |
Validity: | 30 |
Specifications: | |
Quantity: | 1.00 |
Price Description: | |
Detailed Product Description: | The 2013 edition of the peptide drug market investment profitability analysis and development potential study ------------------------------------ - report coding] 35178 [publishers] in research Huatai Research Institute Publication Date] October 2012 [Delivery] the EMIL electronic version or EMS [Price] [paper version]: 6500 yuan [electronic version]: 6800 yuan [paper + E]: 7000 yuan (discount) 【Telephone Order】 010-56231698 [Fax Order] 010-84943629 [Contact] Liu Ya [QQ Consulting] 2419062646 2643395623 [website address] http://www. zyhtyjy.com/report/35178.html (click or copy the website read text) [Contents] Chapter peptide drug industry characteristics analysis of 9 polypeptide defined in Section I and application 9 a definition of polypeptide and Introduction II polypeptide development and the use of 9 three peptides produced 12 a 10 Section II peptide drug classification, definition of polypeptide drugs 12 Second, the peptide drug classification 12 Section III the peptide drug industry characteristics analysis of 15 industry-specific business model of 15 two level of profits of the pharmaceutical industry 15 Third, the technical level of the industry 18 four industry five regional analysis of 19, 19, 2012, downstream associated peptide drug industry development environment in the industry analysis 21 Section I in 2012, China's macroeconomic environment analysis 21, 2012 China's GDP growth to 21, 2012 China's industrial economic development situation analysis 22 III 2012, China's total fixed asset investment analysis 24 4 26 V. 2012, China's urban and rural residents' income and consumption, the total retail sales of consumer goods in China in 2012 28 VI, in 2012 China's foreign trade development situation analysis of 30 Section II of the development of the pharmaceutical industry in 2012 Overview 31, 2012, the scale of the global pharmaceutical market analysis 31 3 Overview of the development of China's pharmaceutical industry in 2011 32, 2012 China's pharmaceutical industry Development Overview 35 4, 2012 sales volume of China's pharmaceutical industry 37 Section III in 2012 the development of China's pharmaceutical industry Analysis 40, 2012, the pharmaceutical industry boom Analysis 40, 2012, the Chinese pharmaceutical industry investment analysis of 41 in 2012, the pharmaceutical industry Production Analysis 44 IV In 2012, the pharmaceutical industry sales of 50 V. In 2012, the pharmaceutical industry in China Import and Export Analysis 55 VI 2012 pharmaceutical price situation analysis analysis of the peptide drug market capacity in 2012 57 Chapter 60 Section I of industry management system and policy analysis 60, 60 two of the management system of the industry, the industry regulatory regime 60 3 62 a, 62 Section II peptide drugs market status quo of the industry regulations and policies, peptide drug development overview 62 two a peptide drug prices 64 three the number of peptide drug candidates 64 peptide drug to become one of the important direction of drug research and development 65 Section III the global peptide drug market 65 one, 65 two of the the global peptide drug market capacity, the peptide products market capacity of 66 Section IV of peptide drugs market capacity 66 , peptide drugs market capacity of 66 two, three chemically synthesized peptide drug market capacity 67, 68 a chemically synthesized peptide drug market structure 68 Section V polypeptide formulations market capacity for injection Thymopentin 68 injection somatostatin 69, acetic acid, ammonia, three 70 four pressurized injection, injection terlipressin of Su 71 Chapter 2012 the peptide drug competition in the market analysis of the 72 first section of industries and enterprises in 72 a, 72 two of the major enterprises of the China Thymopentin market 72 III Somatostatin market enterprises, China to ammonia 72 four of the major enterprises of the vasopressin market, the terlipressin market 72 Section II industry barriers to entry of 73 to the financial barriers 73, talent obstacles 73 three, four policy barriers 73, 73 Section III of the technical barriers to industry development impact factors analysis 74 74 two favorable factors for the development of the industry, the unfavorable factors for the development of the industry 75 Chapter 2012 peptide drug market competition analysis 78 Section I of Shenzhen Han Yu Pharmaceutical Co., Ltd. a 78, 78 of the basic situation of the company, the business situation analysis 79, 81 four business analysis of economic indicators, enterprise profitability analysis 81 five, 81 six corporate solvency analysis, enterprise operational capability (7 of 82) enterprise cost analysis 82 Section II of Hainan Zhonghe Pharmaceutical Co., Ltd., 83 a, the basic situation of the company 83 II, enterprises main economic indicators 83 three corporate solvency analysis 84 four, 85 five corporate profitability analysis, business operations The ability to analyze 86 Section III Hainan double into Pharmaceutical Co., Ltd. 87 Company 87 Second, 87 three of the major economic indicators, corporate solvency analysis of 88 Fourth, the profitability of the business 89 Fifth, the ability of business operations analysis 90 Chapter four the Changzhou Siyao Pharmaceutical Co., Ltd. 90 a Company 90 II, enterprises main economic indicators 91 three corporate solvency analysis 92 Fourth, the profitability of the business 92 business operations capacity 92 Section V Chengdu Diao Pharmaceutical Group Co., Ltd. 93, two 93, 93 three of the major economic indicators, corporate solvency analysis of 94 four, 94 five corporate profitability analysis, analysis of business operations ability 95 of Section VI Merck Serono 95 a , 95 two of the basic situation of the company, the business scope of 96 three, the operation of the company's 100-company developments 101 Section VII Ferring Group 102 a 102 two of the basic situation of the company, the company's products introduced 102 chart catalog chart containing peptides and proteins three stages of life science research in amino acid number of the case 9 Chart 10 Chart 3 2006-2012 China's pharmaceutical industry total profit of Statistics 2006-2012 16 Figure 4 China's pharmaceutical industry profit growth trend in Figure 16 charts 52006-2012 pharmaceutical industry gross profit margin of 17 chart 62006-2012 sales profit rate of China's pharmaceutical industry, the pharmaceutical industry in China in 2006-2012 17 Figure 7 cost margin situation the total assets of China's pharmaceutical industry profit margins 18 Chart 8 2006-2012 18 Chart 9 2006-2011, China's per capita gross domestic product (GDP) trends Figure 21 Chart 10 2006-2012 China's gross domestic product (GDP) growth rate trend graph 22 chart 111998-2011 economic indicators of China's industrial enterprises above designated size 23 Exhibit 12 2006 - 2011 China's total industrial added value growth rate trend chart 23 chart 13 2012 the monthly trend of above-scale industrial added value increased Figure 24 Chart 14 2005-2011 China's total fixed asset investment growth trend Figure 25 Exhibit 15 2012 China size and growth rate of urban fixed asset investment growth trend in Figure 26 Chart 17 2006-2012 total retail sales of consumer goods in China and the growth rate of trend graph Statistics 2012 25 Exhibit 16 monthly investment in fixed assets (excluding farmers) 27 Exhibit 18 2012 Social Figure 28 Chart 19 2006-2012 29 Chart 20 2006-2012 net income of rural residents and the growth of urban residents per capita disposable income and growth trend graph Statistics 30 Chart 21 2006-2012 China's total import and export volume of total retail sales of consumer goods in the chain growth trend trend of the scale of the global pharmaceutical market growth trend in Figure 30 Chart 22 2006-2012 Figure 31 charts 23 2011 economic indicators of China's pharmaceutical industry statistics chart 33 24 2011 Ranking Chart 34 25 2011 Chinese medicine five provinces, autonomous regions, the number of firms in the pharmaceutical industry the industry five provinces Total assets ranking charts 34 26 2011 five provinces and sales revenue of China's pharmaceutical industry rankings chart 34 27 2011 35 Exhibit 28, the total profit of the five provinces of the Chinese pharmaceutical industry rankings 2012 the Chinese pharmaceutical industry and economic indicators statistics 35 Chart 29 Chinese pharmaceutical industry in five provinces, autonomous regions, the number of firms in 2012 # 36 chart 30 2012 total Chinese pharmaceutical industry five provinces assets ranked five provinces and regions of China's pharmaceutical industry sales revenue ranked 37 Exhibit 31 2012 37 Exhibit 32 2012 the total profit of the pharmaceutical industry five provinces ranked 37 Chart 33 2006-2012 sales revenue statistics of China's pharmaceutical industry sales revenue sales revenue growth trend of China's pharmaceutical industry 38 Exhibit 34 2006-2012 38 Figure 35 provinces and autonomous regions in China in 2011, the pharmaceutical industry 38 Exhibit 36 ??in 2012 sales revenue of the pharmaceutical industry, provinces and autonomous regions in China 39 Exhibit 37 business climate index for the country and the pharmaceutical industry in 2009-2012 Chart 41 Chart 38 2010-2012 China's pharmaceutical industry investment in fixed assets of 42 chart 392010-2012 China fixed assets investment of the pharmaceutical industry trends Figure 42 Chart 40 2009-2012 China's pharmaceutical industry investment in fixed assets accounting for changes in trends Figure 43 Chart 41 2009-2012 China's pharmaceutical industry is the use of foreign contract number of items and the amount accounted for 422 010 44 Chart -2012 Chinese pharmaceutical industry, industrial output value of 45 Chart 43 2010-2012 China pharmaceutical industry that month industrial output value trends Figure 45 Chart 44 2010-2012 China's pharmaceutical industry in total industrial output value trends Figure 46 Chart 452010-2012 China's pharmaceutical industry, the growth rate of the value of the current month and the cumulative increase 46 Chart 46 2009-2012 the month and accumulated added value of China's pharmaceutical industry trend Figure 48 Chart 47 Chart 47 2010-2012 China chemical raw materials production in 48 2010-2012 China chemical raw materials when the monthly production trend trend chart in Figure 48 492010-2012 cumulative production of chemical raw materials in China of proprietary Chinese medicines production 49 Chart 50 2010-2012 49 Chart 51 2010-2012 China Chinese patent medicine when the monthly change Trend Figure 50 Chart 52 2010-2012 China Chinese patent medicine cumulative production trends Figure 50 Chart 53 2010-2012 industrial sales output value of China's pharmaceutical industry situation 51 Chart 54 2010-2012 the month industrial sales output value of China's pharmaceutical industry trend chart in Figure 52 552010-2012 accumulated industrial sales output value trends Figure 52 Chart 56 2010-2012 the total retail sales of Chinese and Western medicine, Chinese medicine industry 53 Chart 57 2010-2012 China's total retail sales of Chinese and Western medicines that month trend Figure 53 charts 582010-2012 China's the cumulative total retail sales of Chinese and Western Medicines trend Figure 54 Chart 59 2009-2012 Chart 54 Chart 60 2010-2012 export delivery value of China's pharmaceutical industry, pharmaceutical industry marketing rate 56 Chart 61 2010-2012 China pharmaceutical industry the month export delivery value trends Figure 57 Chart 56 Chart 62 2010-2012 total export delivery value of China's pharmaceutical industry trend charts 63 in 2010-2012 and the pharmaceutical industry, industrial producer price index 58 chart 642009-2012 58 Chart 65 2010-2012 China retail price index of Chinese and Western medicines and health care supplies situation of the country and the pharmaceutical industry, industrial producer prices index chart 59 Chart 66 2010-2012 China Chinese and Western medicines and health care supplies retail price index chart 59 Chart 67 has been formed peptide drug types and uses 63 charts 68 new chemical structure distribution of chemically synthesized peptide drug prices in 2007-2009 64 Chart 69 different years to enter clinical studies of peptide molecules 64 Chart 70 2007-2011 China polypeptides the size of the drug market trend Figure 67 Chart 71 2007-2011 China chemically synthesized peptide drug market scale trend Figure 67 Chart 72 2007-2011 China chemical synthesis of peptide drugs accounted for the entire peptide drug market share 68 Chart 73 2007-2011 China thymopentin market size trend chart in Figure 69 74 2007-2011 somatostatin market size trends Figure 70 Chart 75 2007-2011 China ammonia vasopressin market scale trend Figure 71 Chart 76 2007-2009 chemically synthesized peptide drug formulations distribution of 77 chart 77 2012 the Shenzhen Hybio Pharmaceutical Company Limited income products or services Table 80 charts 78 2012 Shenzhen the Squire Sanders Pharmaceutical Co., Ltd. business structure 80 chart 792,012 in Shenzhen Squire Sanders Pharmaceutical Co., Ltd. regions Table 80 Chart 80 2008-2012 Shenzhen the Squire Sanders Pharmaceutical Corporation income and profits statistics 81 Chart 81 2008-2012 Shenzhen the Squire Sanders Pharmaceutical Co., Ltd. assets and liabilities Statistics 81 81 Chart 83 2008-2012 solvency situation of Squire Sanders Pharmaceutical Co., Ltd., Shenzhen Shenzhen Squire Sanders Pharmaceutical Co., Ltd. profitability situation Chart 82 2008-2012 82 Chart 84 2007-2011 Shenzhen Squire Sanders Pharmaceutical Co., Ltd. the company operational capability of 82 Chart 85 2008-2012 Squire Sanders Pharmaceutical Co., Ltd., Shenzhen costs constitute Statistics 82 chart 862003-2011 Hainan Zhonghe Pharmaceutical Co., Ltd. assets and liabilities Statistics 84 Chart 87 2003-2011 revenue and profit statistics of Hainan Zhonghe Pharmaceutical Co., Ltd. 84 chart 882003-2011 Hainan Zhonghe Pharmaceutical Co., Ltd. solvency Statistics 85 chart 892003-2011 changes in asset-liability ratio of Hainan Zhonghe Pharmaceutical Co., Ltd. trends in Figure 85 charts 902003-2011 Pharmaceutical Co., Ltd., Hainan and profitability statistics Chart 86 912003-2011 Hainan Zhonghe Pharmaceutical Co., Ltd. gross margin trend chart in Figure 86 922003-2011 Hainan Pharmaceutical Co., Ltd. operational capability the Hainan double into the Pharmaceutical Co., the assets and liabilities of Statistics 88 Chart 94 2006-2011 the Hainan double into the Pharmaceutical Co., revenue and profit statistics Statistics 87 Chart 93 2006-2011 88 Chart 952006-2011 years the Hainan double into the Pharmaceutical Co., Ltd. solvency Statistics 88 Chart 96 2006-2011 Hainan double into Pharmaceutical Co., asset-liability ratio change trend Figure 89 Chart 97 2006-2011 Hainan double into Pharmaceutical Co., Ltd. profitability statistics 89 Chart 98 2006-2011 Pharmaceutical Co., Ltd. of Hainan double into gross margin trends Figure 90 Chart 99 2006-2011 Hainan double into Pharmaceutical Co., operational capability Statistics 90 Chart 100 2008-2011 the Changzhou Siyao Pharmaceutical Co., Ltd. assets 92 Exhibit 91 Exhibit 101, 2008-2011 Changzhou Pharmaceutical Co., Ltd. Siyao revenue and profit statistics liabilities Statistics 102 Changzhou Pharmaceutical Co., Ltd. of the four drugs solvency Statistics 2008-2011 92 Chart 103 2008-2011 Pharmaceutical Co., Ltd. Changzhou Siyao earnings Capacity Statistics 92 Chart 104 2008-2011 Changzhou Siyao Pharmaceutical Co., Ltd. operational capability Statistics 93 Chart 105 2008-2011 Chengdu Diao Pharmaceutical Group Co., the assets and liabilities of Statistics 94 chart 106 2008-2011 Chengdu Diao Pharmaceutical Group Co., Ltd. revenue and profit statistics 94 Chart 107 2008-2011 Chengdu Diao Pharmaceutical Group Co., Ltd. solvency statistical charts 94 108 2008-2011 Chengdu Diao Pharmaceutical Group Co., Ltd. profitability Statistics 94 Chart 109 2008-2011 Chengdu Diao Pharmaceutical 95 charts 110 Merck Serono Group Limited operational capacity statistics list 96 Chart 111 2008-2012 Merck Serono operating income trend Figure 100 Chart 112 2008-2012 Merck Serono operating profit trend Figure 100 chart trend of the total assets of the 113 2008-2012 Merck Serono Figure 101 Chart 114 2010-2012 Merck Serono operating income sub-sector Table 101 chart 115 Ferring Pharmaceuticals Co., Ltd. Products 103 reports each quarter can be updated in real time, free service for one year, the specific content and the ordering process is welcome to consult the customer service staff, thank you for your attention! Advantech Huatai Institute - Project hotline 010-56231698 Central Research Institute of China and Thailand - Customer Service Specialist - Liu Ya research Huatai Institute of - Advantech Huatai Institute of Hotline 13391676235 - http :/ / www.zyhtyjy.com, |
Admin>>>
You are the 12214 visitor
Copyright © GuangDong ICP No. 10089450, Beijing Huashang information Co., Ltd. All rights reserved.
Technical support: ShenZhen AllWays Technology Development Co., Ltd.
AllSources Network's Disclaimer: The legitimacy of the enterprise information does not undertake any guarantee responsibility
You are the 12214 visitor
Copyright © GuangDong ICP No. 10089450, Beijing Huashang information Co., Ltd. All rights reserved.
Technical support: ShenZhen AllWays Technology Development Co., Ltd.
AllSources Network's Disclaimer: The legitimacy of the enterprise information does not undertake any guarantee responsibility